a WHO initiative to combat counterfeit medicines

Slides:



Advertisements
Similar presentations
الرابطة الدولية لمكافحة المواد الطبيّة المزورة a WHO initiative to combat counterfeit medical products Dr V. Reggi - World Health Organization.
Advertisements

Armand Racine Consultant Chemicals Branch
Copyright of the Health Sciences Authority 2007 ASEAN-China Conference on Combating Counterfeit Medical Products Jakarta, November 2007 Singapore.
International Medical Products Anti-CounterfeitingTaskforce INSPECTOR OF DRUGS NATIONAL DRUG AUTHORITY- UGANDA.
First ASEAN-China Conference on Combating Counterfeit Medical Products Jakarta November 2007 CHOO CHEOK HANG DEPARTMENT OF PHARMACEUTICAL SERVICES.
A WHO initiative to combat counterfeit medical products Dr V. Reggi World Health Organization.
EUFJE BRUSSELS CONFERENCE 19 Octobre 2010 Joint meeting EUFJE – public prosecutors,
DG Enterprise and Industry Approach on Combating Counterfeit Medicines Council of Europe Conference “Europe against Counterfeit Medicines” Session: Key.
World Health Organization
Competition Culture The Key to Successful Competition Regime 3 rd BRICS International Competition Conference New Delhi, November 21-22, 2013 Pradeep S.
Panel themes of the International Conference “Europe against Counterfeit Medicines” G.N. Gildeeva, Deputy head of the Department of Registration of Medicines.
Strengthening the Protection of Intellectual and Industrial Property Rights Deputy Manager Jan Hylleberg The Danish Association of the Pharmaceutical Industry.
WHO Good Governance for Medicines programme Technical Briefing Seminar 19 November 2009, Geneva Dr Guitelle Baghdadi-Sabeti Department of Essential Medicines.
Examples of Best Practices: Anti- corruption Strategy of the TCA Musa KAYRAK Senior Auditor, CISA.
2011 Overall Objectives Contributing toward limiting Violence against Women, and fostering the role of the NCHR in combating VAW focusing on domestic.
Developing Capacity on Water Integrity WATER INTEGRITY NETWORK Delft 31st May 2013 Francoise Nicole Ndoume Regional Coordinator Water Integrity Network,
Using the UN Convention against Corruption as a Basis for Good Governance.
Whilst the pharmaceutical industry plays a key role in developing and producing medicines, there is a tension between industry’s need to expand product.
Outcomes of Public Health
Criteria for Centres of Expertise for Rare Diseases in the EU following EUCERD Recommendations RARECARENet Project: Consensus meeting on.
THANK YOU!. Regional Adviser, Noncommunicable Diseases, WHO/EMRO Dr Ibtihal Fadhil.
The emergence of an Enforcement Agenda Intellectual Property Rights and Access to Essential Medicines: Challenges and Opportunities in Free Trade Agreement.
Key Elements of Legislation For Disaster Risk Reduction Second Meeting of Asian Advisory Group of Parliamentarians for DRR 5-7 February, 2014, Vientiane,
ASSOCIATION OF STATE PUBLIC HEALTH NUTRITIONISTS.
Committed to Connecting the World International Telecommunication Union Presentation Brief about ICTs Applications activities Telecommunication Development.
EU Funding opportunities : Rights, Equality and Citizenship Programme Justice Programme Jose Ortega European Commission DG Justice.
Third OIE Global Conference on Animal Welfare Kuala Lumpur, Malaysia The OIE PVS Pathway Dr. Mariela Varas OIE International Trade Department.
ACCESS TO MEDICINES - POLICY AND ISSUES
Policy track summary ICIUM 2011 – 18 Nov Policy track topics 1.The pharmaceutical policy process 2.Quality and safety of medicines in LMIC 3.Policy.
April_2010 Partnering initiatives at country level Proposed partnering process to build a national stop tuberculosis (TB) partnership.
HTA Benefits and Risks Dr Bernard Merkel European Commission.
AC Workshop _ Bratislava - March 2011 UNDP BRC, capacity development for prevention of corruption Francesco Checchi, Anti-Corruption Programme Coordinator.
Public health, innovation and intellectual property 1 |1 | The Global Strategy on Public Health, Innovation and Intellectual Property Technical Briefing.
WHO Regional Workshop on Good Manufacturing Practices for Blood Establishments Dr Ana Padilla, Blood Products & related Biologicals Essential Medicines.
Strategic Objective 4 To promote the exchange of experiences and regulatory knowledge between NRAs inside and outside PANDRH“ Lessons learned from international.
Ministerial Declaration and Concluding Remarks MD PhD Karin Tegmark Wisell Chair AMR expert group, NDPHS.
The First Conference for Medicines Regulatory Authorities In Sudan and Neighboring Countries Khartoum December 2014 Alain PRAT, Technical Officer,
Workshop on “EU Enlargement: Regulatory Convergence in Non-acceding Countries” Athens 7 – 8 November 2003 Regulatory Convergence and Technical Standards.
European network for Health Technology Assessment | JA | EUnetHTA European network for Health Technology Assessment THL Info.
Project “Transition policy trends in indigenous, rural and border communities” May Bolivia, Chile, Colombia, Costa Rica, Guatemala, Mexico, Peru.
ITC-ILO/ACTRAV Course A Trade Union Training on Occupational Safety, Health & HIV/AIDS (26/11 – 07/12/2012, Turin) Introduction to National Occupational.
Project: EaP countries cooperation for promoting quality assurance in higher education Maria Stratan European Institute for Political Studies of Moldova.
Corruption Risk Assessment for REDD+ : Kenya’s experience Geneva, Switzerland 8 December 2013.
Civil Society Participation and Contribution to the UNCAC Review Process Towards Transparency – TI National Contact Vietnam UNCAC Self Assessment Process:
ACCESS TO QUALITY MEDICINES IN THE REGION-COUNTERFEITING PROBLEMS
Improving the Garment Sector in Lao PDR:
Implementation of 2016 Work Plan ASA EG
Global and national approaches to reducing the harmful use of alcohol
EYV 2011 Alliance Céline Barlet (Project Officer) 1.
Outline Responsible authorities for reporting under the IHR
IFOAM organizations Brief overview of IFOAM Organics International, IFOAM EU Group and IFOAM AgriBioMediterraneo.
Addressing violence against women in the Americas: the role of health systems Special Meeting of The Permanent Council On The Subject “Addressing Violence.
The value of UNCAC Session 5.
Establishing the Infrastructure for Radiation Safety Preparatory Actions and Initial Regulatory Activities.
Quality Assurance and Safety of Medicines
Declaration of the 11th ministerial-level PAC meeting in Berlin 2015 From strategies to action – how to tackle the challenges of Antimicrobial Resistance.
EU Reference Centres for Animal Welfare
Planning a Learning Unit
Civil Protection Financial Instrument – Prevention Projects
Vision, Mission, and Goals
Hungarian Integrity Management Development
…and still actual for a post-2010 strategy!
Regulation of Medical Products & Patient Safety- A Narrative Review
Medicines Safety Mary R. Couper
Marleen De Smedt Geoffrey Thomas Cynthia Tavares
Dr Manisha Shridhar Regional Advisor WHO-SEARO
EDUCATION SECTOR STRATEGIC PLAN FOR HIV/AIDS PREVENTION
STRUCTURE AND METHODS OF CO-OPERATION
UNODC and CYBERCRIME October 2009.
Presentation transcript:

a WHO initiative to combat counterfeit medicines Dr V. Reggi World Health Organization

Combating counterfeit medicines What is “counterfeiting medicines”? Pourquoi devons-nous en parler? Que devrions-nous faire?

What is ‘counterfeiting medicines’? (1) To manufacture and give unaware patients ‘medicines’ that . . . are not medicines Arbitrary and unpredictable composition: no active ingredient, another active ingredient, wrong amount, bad quality First of all, what is Known Good Quality? Known Good Quality refers to vaccines which are licensed, controlled and released by an NCA which exercises the six critical control functions and there are no unresolved quality problems reported The six critical control functions are those which have been determined by the WHO Expert Committee on Biological Standardization, an expert group drawn from a panel representing the most knowledgeable authorities from all regions of the world, to be essential to the task of a competent and independent NCA. The need for their exercise will vary with the vaccine source.

What is ‘counterfeiting medicines’? (2) A vile and serious crime threatening everybody’s health, including that of law makers, health ministers, directors of health services, inspectors, policemen, customs officers, corrupt civil servants, …… … as well as their families and friends! First of all, what is Known Good Quality? Known Good Quality refers to vaccines which are licensed, controlled and released by an NCA which exercises the six critical control functions and there are no unresolved quality problems reported The six critical control functions are those which have been determined by the WHO Expert Committee on Biological Standardization, an expert group drawn from a panel representing the most knowledgeable authorities from all regions of the world, to be essential to the task of a competent and independent NCA. The need for their exercise will vary with the vaccine source.

It is a public health problem! What is ‘counterfeiting medicines’? (3) It is not an intellectual property problem! It is a public health problem! It threatens everybody’s life and undermines the credibility of our health care delivery and pharmaceutical supply systems! First of all, what is Known Good Quality? Known Good Quality refers to vaccines which are licensed, controlled and released by an NCA which exercises the six critical control functions and there are no unresolved quality problems reported The six critical control functions are those which have been determined by the WHO Expert Committee on Biological Standardization, an expert group drawn from a panel representing the most knowledgeable authorities from all regions of the world, to be essential to the task of a competent and independent NCA. The need for their exercise will vary with the vaccine source.

What is ‘counterfeiting medicines’? (4) It is a problem that has consequences becoming evident at the national level …… … …but with international dimensions, transactions and ramifications First of all, what is Known Good Quality? Known Good Quality refers to vaccines which are licensed, controlled and released by an NCA which exercises the six critical control functions and there are no unresolved quality problems reported The six critical control functions are those which have been determined by the WHO Expert Committee on Biological Standardization, an expert group drawn from a panel representing the most knowledgeable authorities from all regions of the world, to be essential to the task of a competent and independent NCA. The need for their exercise will vary with the vaccine source.

What is ‘counterfeiting medicines’? (5) It is a “murderous attack on the sick”! It is therefore a direct challenge to all health professionals, who have made caring for sick their mission First of all, what is Known Good Quality? Known Good Quality refers to vaccines which are licensed, controlled and released by an NCA which exercises the six critical control functions and there are no unresolved quality problems reported The six critical control functions are those which have been determined by the WHO Expert Committee on Biological Standardization, an expert group drawn from a panel representing the most knowledgeable authorities from all regions of the world, to be essential to the task of a competent and independent NCA. The need for their exercise will vary with the vaccine source.

What is ‘counterfeiting medicines’? (6) WHO definition “a medicine, which is deliberately and fraudulently mislabelled with respect to identity and/or source.  Counterfeiting can apply to both branded and generic products and counterfeit products may include products with the correct ingredients or with the wrong ingredients, without active ingredients, with insufficient active ingredients or with fake packaging” First of all, what is Known Good Quality? Known Good Quality refers to vaccines which are licensed, controlled and released by an NCA which exercises the six critical control functions and there are no unresolved quality problems reported The six critical control functions are those which have been determined by the WHO Expert Committee on Biological Standardization, an expert group drawn from a panel representing the most knowledgeable authorities from all regions of the world, to be essential to the task of a competent and independent NCA. The need for their exercise will vary with the vaccine source.

Combating counterfeit medicines What is counterfeiting medicines? Why should we talk about it? Que devrions-nous faire?

Why should we talk about it? Because it is there! Because it is not dwindling, on the contrary, it is growing! Because if we don’t do anything, it will continue to grow! First of all, what is Known Good Quality? Known Good Quality refers to vaccines which are licensed, controlled and released by an NCA which exercises the six critical control functions and there are no unresolved quality problems reported The six critical control functions are those which have been determined by the WHO Expert Committee on Biological Standardization, an expert group drawn from a panel representing the most knowledgeable authorities from all regions of the world, to be essential to the task of a competent and independent NCA. The need for their exercise will vary with the vaccine source.

Why should we talk about it? (PSI 2006) First of all, what is Known Good Quality? Known Good Quality refers to vaccines which are licensed, controlled and released by an NCA which exercises the six critical control functions and there are no unresolved quality problems reported The six critical control functions are those which have been determined by the WHO Expert Committee on Biological Standardization, an expert group drawn from a panel representing the most knowledgeable authorities from all regions of the world, to be essential to the task of a competent and independent NCA. The need for their exercise will vary with the vaccine source.

Top Ten Ranked by Counterfeits Seized/Discovered Continuing Increase in the Detection of Counterfeit Medicines (PSI, 2006) Top Ten Ranked by Counterfeits Seized/Discovered Country Seizures/Discoveries 1 Russian Federation 93 2 China 87 3 Korea 66 4 Peru 54 5 Colombia 50 6 USA 42 7 UK 39 8 Ukraine 28 9 Germany 25 10 Israel

Combating counterfeit medicines What is counterfeiting medicines? Why should we talk about it? What should we do?

International Conference: What should we do? International Conference: 16-18 February 2006 – Rome 160 participants: 57 national authorities, 7 international organisations, 12 international associations representing patients, health professionals, manufacturers, wholesalers First of all, what is Known Good Quality? Known Good Quality refers to vaccines which are licensed, controlled and released by an NCA which exercises the six critical control functions and there are no unresolved quality problems reported The six critical control functions are those which have been determined by the WHO Expert Committee on Biological Standardization, an expert group drawn from a panel representing the most knowledgeable authorities from all regions of the world, to be essential to the task of a competent and independent NCA. The need for their exercise will vary with the vaccine source. IMPACT: International Medical Products Anti-Counterfeiting Taskforce

What is IMPACT ? IMPACT is a taskforce launched by WHO to gather all the most important international actors in the fight against counterfeiting IMPACT aims at coordinating global action against the counterfeiting of medical products in order to promote and protect public health. First of all, what is Known Good Quality? Known Good Quality refers to vaccines which are licensed, controlled and released by an NCA which exercises the six critical control functions and there are no unresolved quality problems reported The six critical control functions are those which have been determined by the WHO Expert Committee on Biological Standardization, an expert group drawn from a panel representing the most knowledgeable authorities from all regions of the world, to be essential to the task of a competent and independent NCA. The need for their exercise will vary with the vaccine source.

Counterfeits frustrate efforts to deal with high burdens of disease. Why do we need IMPACT ? Counterfeits have harmful effects on patients' health, including death. Counterfeits frustrate efforts to deal with high burdens of disease. Counterfeits undermine the credibility of health care delivery systems. Globalization of economies is helping to ‘globalize’ the problem. Increased commercial use of the Internet also contributes to the expansion of the problem. First of all, what is Known Good Quality? Known Good Quality refers to vaccines which are licensed, controlled and released by an NCA which exercises the six critical control functions and there are no unresolved quality problems reported The six critical control functions are those which have been determined by the WHO Expert Committee on Biological Standardization, an expert group drawn from a panel representing the most knowledgeable authorities from all regions of the world, to be essential to the task of a competent and independent NCA. The need for their exercise will vary with the vaccine source.

Who can participate in IMPACT ? All 192 WHO Member States and all major international stakeholders, such as: European Commission First of all, what is Known Good Quality? Known Good Quality refers to vaccines which are licensed, controlled and released by an NCA which exercises the six critical control functions and there are no unresolved quality problems reported The six critical control functions are those which have been determined by the WHO Expert Committee on Biological Standardization, an expert group drawn from a panel representing the most knowledgeable authorities from all regions of the world, to be essential to the task of a competent and independent NCA. The need for their exercise will vary with the vaccine source.

How does/will IMPACT work? IMPACT shall function on the basis of existing structures/institutions and will in the long term explore further mechanisms for strengthening international action against counterfeit medicines 5 working groups: legislative and regulatory infrastructure regulatory implementation enforcement technology communication First of all, what is Known Good Quality? Known Good Quality refers to vaccines which are licensed, controlled and released by an NCA which exercises the six critical control functions and there are no unresolved quality problems reported The six critical control functions are those which have been determined by the WHO Expert Committee on Biological Standardization, an expert group drawn from a panel representing the most knowledgeable authorities from all regions of the world, to be essential to the task of a competent and independent NCA. The need for their exercise will vary with the vaccine source.

LEGISLATIVE & REGULATORY INFRASTRUCTURE survey existing national and international legislation & requirements; assess gaps in existing national and international legislation & requirements on manufacturing, distribution, exportation, and importation; develop guiding principles for legislation; develop initiatives aimed at law-makers in order to promote adoption of new legislation; requirements for the distribution system; assess existing national best practices and develop model best practices.

REGULATORY IMPLEMENTATION promote implementation of Good Manufacturing, Good Distribution and Good Pharmacy Practice guidelines and quality assurance systems to ensure supply chain integrity; develop model training materials aimed at improving quality assurance within and supervision of distribution chain; develop guidance on the role of quality control laboratories in combating counterfeit drugs; develop data collection tools and methodologies to assess national regulatory and enforcement systems in order to identify gaps and measures needed; at the request of national authorities develop ad hoc projects to improve capacity to combat counterfeit medicines; promote secure exchange of information and alerts among regulatory and/or enforcement officials as appropriate; promote networking and collaboration among national drug regulatory authorities; develop guidance for pharmacovigilance systems to include reporting and investigating suspected cases of counterfeit medicines.

ENFORCEMENT develop advocacy materials to increase resources available for enforcement; promote multi-country initiatives to improve coordination and information exchange among enforcement institutions and officers; develop projects aimed at improving communication and collaboration between regulatory and enforcement officers; develop training materials and manuals to improve skills of enforcement officers; identify gaps in existing legislation, need for resources and propose solutions.

TECHNOLOGY assess (including piloting when feasible and necessary) technologies to prevent, deter, or help to detect counterfeit products taking into account: a) cost, b) scalability, c) specific country needs and situations, d) feasibility, e) regulatory implications; facilitate exchange of information on technologies and their implementation disseminate information and recommendations on the merits and limitations of technologies

COMMUNICATION develop agreed messages and ensure IMPACT presence, as appropriate, at important national and international events; develop advocacy, risk communication and education strategies and materials taking into account the need to address specific target groups such as patients and health professionals; develop more effective collection and analysis of information on suspected and confirmed cases of counterfeit medical products and dissemination of confirmed cases as appropriate; develop initiatives to communicate risks of purchasing medicines from unknown sources (e.g. Internet); assist national authorities to develop risk communication and advocacy materials.

IMPACT toolkit Experience from different countries; Model legislation & regulations; Training materials and methodologies; Tools and manuals to assist national authorities in implementing activities; Tools and methodologies for the assessment of national/regional situations.

collaboration among all those concerned is essential “IMPACT approach”: collaboration among all those concerned is essential BORDER CONTROL BODIES JUDICIARY PERIPHERAL PUBLIC SECTOR INSTITUTIONS POLICE & OTHER ENFORCEMENT BODIES DRUG REGULATORY AUTHORITIES OTHER PUBLIC SECTOR INSTITUTIONS PATIENTS HEALTH PROFESSIONALS DISTRIBUTION CHANNEL MANUFACTURERS

IMPACT NEEDS YOU! PROFESSION’S REPUTATION NEEDS YOU! FAKE DRUG BOMB

Help!! Report and help investigating cases Increase security and transparency of distribution systems In many countries pharmacists’ monopoly is an illusion: if you do not organize informal networks others will do it support IMPACT working groups (e.g. training materials, risk communication, regulation of distribution chain, exchange information...)

Thank you